🚨Paper Alert🚨
Thrilled to share this paper published in the @agsjournal.bsky.social , on the prevalence of anticholinergic and sedative drugs used in older adults (aged 65+)💊🧠
👉data from the 🇫🇷French National Health Data System (#SNDS)
👉n=16,938,152
🚨prevalence=32.8%
https://shorturl.at/0PsQF
🧵👇1/
Thrilled to share this paper published in the @agsjournal.bsky.social , on the prevalence of anticholinergic and sedative drugs used in older adults (aged 65+)💊🧠
👉data from the 🇫🇷French National Health Data System (#SNDS)
👉n=16,938,152
🚨prevalence=32.8%
https://shorturl.at/0PsQF
🧵👇1/
Comments
👏 🙏 study led by the brilliant @teddynovais.bsky.social and F Gervais, 👏 to co-authors E. Reallon & C. Mouchoux. 🤩it's fantastic to work with this clinical pharmacy team🤩
https://shorturl.at/0PsQF
🧵5/5
🥇 oxazepam (5.27%), alprazolam (5.27%), zopiclone (4.85%), bromazepam (4.23%), metopimazine (2.88%), paroxetine (2.70%), nefopam (2.57%), and hydroxyzine (2.17% 😱).
🧵4/
- All people aged > 65 years in 2023 were included in this study.
- Dispensations of Ac/S medications were identified according to PIM criteria (2023 AGS Beers Criteria and REMEDI[e]S tool).
🧵3/
Anticholinergic/Sedative (Ac/S) drugs in older adults 👉 associated with falls, frailty, delirium, and functional and cognitive impairment and are potentially inappropriate medications (PIMs).
We examined the prevalence of Ac/S drugs to avoid in older people in 🇫🇷 in 2023.
🧵2/